Duchenne muscular dystrophy (DMD) is the most common and deadly type of muscular dystrophy. It is characterized by progressive wasting and weakness due to disturbances of a protein called ‘dystrophin’, which helps keep cells intact.
The disease mainly affects male children, but on rare occasions it can also be seen in females.
The current therapeutic options available to treat DMD are minimal and very expensive, with skyrocketing costs, and most are imported from abroad, putting them out of reach for most families.
The Indian Institute of Technology Jodhpur established a research center in collaboration with the Bengaluru Dystrophy Annihilation Research Trust and the All India Institute of Medical Sciences Jodhpur to develop affordable therapies to treat this rare and incurable genetic disorder.